1. |
Hoogendijk JE, Amato AA, Lecky BR, et al. 1119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul Disord, 2004, 14(5): 337-345.
|
2. |
Suzuki S, Hayashi YK, Kuwana M, et al. Myopathy associated with antibodies to signal recognition particle: disease progression and neurological outcome. Arch Neurol, 2012, 69(6): 728-732.
|
3. |
Targoff IN, Johnson AE, Miller FW. Antibody to signal recognition particle in polymyositis. Arthritis Rheum, 1990, 33(9): 1361-1370.
|
4. |
Watanabe Y, Uruha A, Suzuki S, et al. Clinical features and prognosis in anti-SRP and anti-HMGCR necrotising myopathy. J Neurol Neurosurg Psychiatry, 2016, 87(10): 1038-1044.
|
5. |
Amato AA, Greenberg SA. Inflammatory myopathies. Continuum (Minneap Minn), 2013, 19(6): 1615-1633.
|
6. |
Dalakas MC. Inflammatory muscle diseases. N Engl J Med, 2015, 372(18): 1734-1747.
|
7. |
Shelly S, Mielke MM, Paul P, et al. Incidence and prevalence of immune-mediated necrotizing myopathy in adults in Olmsted County, Minnesota. Muscle Nerve, 2022, 65(5): 541-546.
|
8. |
Klein M, Mann H, Pleštilová L, et al. Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience. Rheumatology (Oxford), 2015, 54(11): 2010-2014.
|
9. |
Prieto-Peña D, Ocejo-Vinyals JG, Mazariegos-Cano J, et al. Epidemiological and genetic features of anti-3-hydroxy-3-methylglutaryl-CoA reductase necrotizing myopathy: single-center experience and literature review. Eur J Intern Med, 2022, 101: 86-92.
|
10. |
Vencovský J. Immune mediated necrotizing myopathy associated with statin treatment. Cas Lek Cesk, 2016, 155(6): 319-323.
|
11. |
Allenbach Y, Mammen AL, Benveniste O, et al. 224th ENMC International Workshop: clinico-sero-pathological classification of immune-mediated necrotizing myopathies zandvoort, the Netherlands, 14-16 October 2016. Neuromuscul Disord, 2018, 28(1): 87-99.
|
12. |
Suzuki S, Nishikawa A, Kuwana M, et al. Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet J Rare Dis, 2015, 10: 61.
|
13. |
Tiniakou E, Pinal-Fernandez I, Lloyd TE, et al. More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Rheumatology (Oxford), 2017, 56(5): 787-794.
|
14. |
Pinal-Fernandez I, Mammen AL. Spectrum of immune-mediated necrotizing myopathies and their treatments. Curr Opin Rheumatol, 2016, 28(6): 619-624.
|
15. |
Pinal-Fernandez I, Parks C, Werner JL, et al. Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle. Arthritis Care Res (Hoboken), 2017, 69(2): 263-270.
|
16. |
Kurashige T. Anti-HMGCR myopathy: clinical and histopathological features, and prognosis. Curr Opin Rheumatol, 2021, 33(6): 554-562.
|
17. |
Allenbach Y, Arouche-Delaperche L, Preusse C, et al. Necrosis in anti-SRP+ and anti-HMGCR+myopathies: role of autoantibodies and complement. Neurology, 2018, 90(6): e507-e517.
|
18. |
Allenbach Y, Keraen J, Bouvier AM, et al. High risk of cancer in autoimmune necrotizing myopathies: usefulness of myositis specific antibody. Brain, 2016, 139(8): 2131-2135.
|
19. |
Benveniste O, Drouot L, Jouen F, et al. Correlation of anti-signal recognition particle autoantibody levels with creatine kinase activity in patients with necrotizing myopathy. Arthritis Rheum, 2011, 63(7): 1961-1971.
|
20. |
Werner JL, Christopher-Stine L, Ghazarian SR, et al. Antibody levels correlate with creatine kinase levels and strength in anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy. Arthritis Rheum, 2012, 64(12): 4087-4093.
|
21. |
Pinal-Fernandez I, Casal-Dominguez M, Mammen AL. Immune-mediated necrotizing myopathy. Curr Rheumatol Rep, 2018, 20(4): 21.
|
22. |
Fionda L, Lauletta A, Leonardi L, et al. Muscle MRI in immune-mediated necrotizing myopathy (IMNM): implications for clinical management and treatment strategies. J Neurol, 2023, 270(2): 960-974.
|
23. |
Zheng Y, Liu L, Wang L, et al. Magnetic resonance imaging changes of thigh muscles in myopathy with antibodies to signal recognition particle. Rheumatology (Oxford), 2015, 54(6): 1017-1024.
|
24. |
Pinal-Fernandez I, Casal-Dominguez M, Carrino JA, et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann Rheum Dis, 2017, 76(4): 681-687.
|
25. |
乔凌亚, 石强, 蔺颖, 等. 免疫介导坏死性肌病患者临床、股部磁共振及电生理特征分析. 中华内科杂志, 2022, 61(10): 1144-1151.
|
26. |
Anquetil C, Boyer O, Wesner N, et al. Myositis-specific autoantibodies, a cornerstone in immune-mediated necrotizing myopathy. Autoimmun Rev, 2019, 18(3): 223-230.
|
27. |
Benveniste O, Stenzel W, Allenbach Y. Advances in serological diagnostics of inflammatory myopathies. Curr Opin Neurol, 2016, 29(5): 662-673.
|
28. |
Allenbach Y, Benveniste O, Stenzel W, et al. Immune-mediated necrotizing myopathy: clinical features and pathogenesis. Nat Rev Rheumatol, 2020, 16(12): 689-701.
|
29. |
Wang L, Liu L, Hao H, et al. Myopathy with anti-signal recognition particle antibodies: clinical and histopathological features in Chinese patients. Neuromuscul Disord, 2014, 24(4): 335-341.
|
30. |
Bergua C, Chiavelli H, Allenbach Y, et al. In vivo pathogenicity of IgG from patients with anti-SRP or anti-HMGCR autoantibodies in immune-mediated necrotising myopathy. Ann Rheum Dis, 2019, 78(1): 131-139.
|
31. |
Ma X, Xu L, Li Y, et al. Immunotherapy reversed myopathy but not cardiomyopathy in a necrotizing autoimmune myopathy patient with positive anti-SRP and MDA-5 autoantibodies. BMC Cardiovasc Disord, 2021, 21(1): 88.
|
32. |
Hara A, Amano R, Yokote H, et al. Secondary cardiac involvement in anti-SRP-antibody-positive myopathy: an 87-year-old woman with heart failure symptoms as the first clinical presentation. BMC Neurol, 2020, 20(1): 29.
|
33. |
Takeguchi-Kikuchi S, Hayasaka T, Katayama T, et al. Anti-signal recognition particle antibody-positive necrotizing myopathy with secondary cardiomyopathy: the first myocardial biopsy- and multimodal imaging-proven case. Intern Med, 2019, 58(21): 3189-3194.
|
34. |
Allenbach Y, Drouot L, Rigolet A, et al. Anti-HMGCR autoantibodies in European patients with autoimmune necrotizing myopathies: inconstant exposure to statin. Medicine (Baltimore), 2014, 93(3): 150-157.
|
35. |
Thiébaut M, Terrier B, Menacer S, et al. Antisignal recognition particle antibodies-related cardiomyopathy. Circulation, 2013, 127(5): e434-e436.
|
36. |
Mavrogeni S, Sfikakis PP, Dimitroulas T, et al. Cardiac and muscular involvement in idiopathic inflammatory myopathies: noninvasive diagnostic assessment and the role of cardiovascular and skeletal magnetic resonance imaging. Inflamm Allergy Drug Targets, 2014, 13(3): 206-216.
|
37. |
Hou Y, Shao K, Yan Y, et al. Anti-HMGCR myopathy overlaps with dermatomyositis-like rash: a distinct subtype of idiopathic inflammatory myopathy. J Neurol, 2022, 269(1): 280-293.
|
38. |
Williams B, Horn MP, Banz Y, et. al. Cutaneous involvement in anti-HMGCR positive necrotizing myopathy. J Autoimmun, 2021, 123: 102691.
|
39. |
Arouche-Delaperche L, Allenbach Y, Amelin D, et al. Pathogenic role of anti-signal recognition protein and anti-3-Hydroxy-3-methylglutaryl-CoA reductase antibodies in necrotizing myopathies: myofiber atrophy and impairment of muscle regeneration in necrotizing autoimmune myopathies. Ann Neurol, 2017, 81(4): 538-548.
|
40. |
Ladislau L, Arouche-Delaperche L, Allenbach Y, et al. Potential pathogenic role of anti-signal recognition protein and anti-3-hydroxy-3-methylglutaryl-CoA reductase antibodies in immune-mediated necrotizing myopathies. Curr Rheumatol Rep, 2018, 20(9): 56.
|
41. |
Lim J, Rietveld A, De Bleecker JL, et al. Seronegative patients form a distinctive subgroup of immune-mediated necrotizing myopathy. Neurol Neuroimmunol Neuroinflamm, 2018, 6(1): e513.
|
42. |
Ma X, Xu L, Ji S, et al. The clinicopathological distinction between seropositive and seronegative immune-mediated necrotizing myopathy in China. Front Neurol, 2021, 12: 670784.
|
43. |
Schmidt J. Current classification and management of inflammatory myopathies. J Neuromuscul Dis, 2018, 5(2): 109-129.
|
44. |
Kassardjian CD, Lennon VA, Alfugham NB, et al. Clinical features and treatment outcomes of necrotizing autoimmune myopathy. JAMA Neurol, 2015, 72(9): 996-1003.
|
45. |
Meyer A, Troyanov Y, Drouin J, et al. Statin-induced anti-HMGCR myopathy: successful therapeutic strategies for corticosteroid-free remission in 55 patients. Arthritis Res Ther, 2020, 22(1): 5.
|
46. |
梁惠玉, 卢家红. 免疫抑制剂在特发性炎性肌病治疗中的应用. 上海医药, 2016, 37(1): 21-24.
|
47. |
彭丽萍, 万月华, 李坤鹏, 等. 免疫介导的坏死性肌病的临床特征及治疗策略研究. 解放军医学院学报, 2022, 43(8): 835-839, 844.
|
48. |
Ramanathan S, Langguth D, Hardy TA, et al. Clinical course and treatment of anti-HMGCR antibody-associated necrotizing autoimmune myopathy. Neurol Neuroimmunol Neuroinflamm, 2015, 2(3): e96.
|
49. |
Gordon PA, Winer JB, Hoogendijk JE, et al. Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis. Cochrane Database Syst Rev, 2012, 2012(8): CD003643.
|
50. |
Mammen AL, Tiniakou E. Intravenous immune globulin for statin-triggered autoimmune myopathy. N Engl J Med, 2015, 373(17): 1680-1682.
|
51. |
季苏琼, 李悦, 徐丽, 等. 肌钙蛋白对于免疫介导的坏死性肌病合并心脏损伤患者的意义. 神经损伤与功能重建, 2020, 15(4): 201-203, 206.
|